NASDAQ$VKTX
Viking Therapeutics Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported first quarter 2020 financial results and provided a corporate update.
Viking Therapeutics reported a net loss of $9.7 million, or $0.13 per share, for the first quarter ended March 31, 2020. The company ended the quarter with $269.2 million in cash, cash equivalents and short-term investments.
- Enrollment continues in Phase 2b VOYAGE study of VK2809 in NASH.
- New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL.
- IND Filing for VK0214 in X-ALD on Track for Mid-Year.
- Balance sheet remains strong, Quarter-End Cash Approximately $270 Million.
Headline financials
Revenue & EPS history
Viking Therapeutics · Revenue · Quarterly
$0
Forward guidance
Viking anticipates completion of enrollment in VOYAGE in the first half of 2021. The company currently expects to submit an IND for VK0214 this summer and initiate clinical studies with this candidate in the third quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+1.6%
Avg return
Earnings day
+4.3%
Avg return
5 days after
+10.3%
Avg return
30 days after
48%
21 / 44 earnings
Positive
+25.5%
Q2 2024
Best reaction
-12.1%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.8% | -0.1% | +4.4% | |
| Q4 2025 | +6.8% | +6.7% | +24.8% | |
| Q3 2025 | +8.1% | +11.2% | +9.0% | |
| Q1 2025 | -0.5% | +8.3% | +4.6% | |
| Q4 2024 | -6.1% | -10.6% | -13.1% | |
| Q3 2024 | +18.0% | +20.1% | -15.2% | |
| Q2 2024 | +25.5% | +18.8% | +25.4% | |
| Q1 2024 | +6.1% | +16.2% | -3.4% | |
| Q4 2023 | +17.4% | +28.9% | +191.7% | |
| Q3 2023 | -9.2% | -10.0% | +15.3% | |
| Q2 2023 | -5.4% | +0.1% | -6.0% | |
| Q1 2023 | -1.4% | +11.3% | +7.2% | |
| Q4 2022 | +7.2% | +6.7% | +3.9% | |
| Q3 2022 | -1.5% | +0.2% | -2.0% | |
| Q2 2022 | -2.1% | -12.0% | +2.1% | |
| Q1 2022 | +5.7% | +10.5% | +1.7% | |
| Q4 2021 | +12.8% | +4.5% | -11.4% | |
| Q3 2021 | +5.5% | +3.0% | -22.9% | |
| Q2 2021 | +6.5% | +6.5% | +9.5% | |
| Q1 2021 | +0.5% | +0.3% | -15.9% | |
| Q4 2020 | -11.1% | -15.2% | -25.7% | |
| Q3 2020 | +0.2% | +0.4% | +19.9% | |
| Q2 2020 | +14.4% | +10.8% | +3.6% | |
| Q1 2020 | -12.1% | +7.9% | +15.3% | |
| Q4 2019 | -6.4% | -4.4% | -28.9% | |
| Q3 2019 | +12.0% | +19.8% | +6.0% | |
| Q2 2019 | -5.9% | -6.0% | -9.6% | |
| Q1 2019 | +7.9% | +6.2% | -1.9% | |
| Q4 2018 | -3.3% | +6.5% | +17.2% | |
| Q3 2018 | -4.4% | -14.6% | -29.9% | |
| Q2 2018 | -0.2% | +3.0% | +8.6% | |
| Q1 2018 | +9.8% | +10.0% | +133.4% | |
| Q4 2017 | -7.1% | -0.2% | -27.2% | |
| Q3 2017 | -5.2% | +16.9% | +76.6% | |
| Q2 2017 | +6.3% | +8.4% | +21.1% | |
| Q1 2017 | -5.1% | -9.4% | -8.7% | |
| Q4 2016 | -7.8% | -7.8% | +6.2% | |
| Q3 2016 | +10.0% | +18.0% | +12.0% | |
| Q2 2016 | -3.8% | -3.8% | +2.3% | |
| Q1 2016 | +5.9% | — | — | |
| Q4 2015 | -10.7% | — | — | |
| Q3 2015 | -9.9% | — | — | |
| Q2 2015 | +5.7% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro